Tag:
Vernalis
Latest Headlines
Latest Headlines
Novartis lists its top blockbuster prospects for '11-'15
The UK's Vernalis has picked up a key endorsement from Novartis, a Big Pharma company with a growing reputation for picking winners in the pipeline. On the same day that Novartis wowed analysts with
Lundbeck forges CNS pact with Zenobia, Vernalis
Denmark's Lundbeck has forged development pacts with Vernalis as well as Zenobia Therapeutics on an brain enzyme inhibition program designed to target CNS (central nervous system) ailments such as
Vernalis spikes troubled V3381 program
The U.K'.s Vernalis says that interim data from a pilot study of V3381 for chronic cough along with the data from a Phase IIb study in neuropathic pain convinced the developer to spike any further
Vernalis Parkinson's drug sinks on tox issues
Vernalis and partner Biogen Idec have halted development of the drug vipadenant (V2006/BIIB014), an A2A receptor antagonist program in development for the treatment of Parkinson's. Though the drug
Vernalis CEO insists he's hunting for new drug deals
The CEO of the UK's Vernalis isn't letting a recent clinical trial setback distract him from growing the company's pipeline. Chief Executive Ian Garland was out this morning talking up new plans to
Vernalis shares dive after pain program flunks PhIIb
Shares of Vernalis tumbled about 20 percent this morning after the UK developer announced that one of its experimental drugs failed a Phase IIb clinical trial for diabetes-related neuropathic pain.
Vernalis, GSK forge $200M cancer research pact
The UK's Vernalis has garnered a fresh injection of cash and stands to gain more than $200 million in fees and milestones from a new research pact it forged with pharma giant GlaxoSmithKline.
Vernalis to raise 24M pounds
The UK's Vernalis says that it intends to raise 24 million pounds sterling to help advance its own programs and possibly buy up some distressed biotech assets. Vernalis will issue more than 800
Vernalis names new CEO, CFO
Two former Acambis execs have found a home at Vernalis . The UK-based company appointed Ian Garland to the top spot and named David Mackney as its new CFO. Garland will begin his tenure at the company
Vernalis inks financing deal
Vernalis has signed a €18.4M financing agreement with Paul Capital Healthcare for frovatriptan, Vernalis' migraine drug. In return for the cash, Paul Capital Healthcare will receive
